Intelligent Antibody Discovery

News

Abeome to Present New Data on IL-25 Asthma Program at Keystone Asthma: From Pathway Biology to Precision Therapeutics

Posted on February 3rd, 2017

Athens, Georgia, February 3, 2017 – Abeome Corporation will present 2 posters at Keystone February 13-16, 2017 describing significant advancements in its IL-25 asthma program. For more information see: Keystone_IL25_Abeome_3026 and: Keystone_IL25_Abeome_1005

Abeome Awarded $1.5M Grant for Technology and Therapeutic Antibody Development

Posted on September 22nd, 2016

Abeome Corporation announced today that it has received notification from the National Institute of Health – National Heart, Blood and Lung Institute of an award granting $1,482,472 over two years for the further development of proprietary monoclonal antibodies in Abeome’s portfolio.

Abeome Honored by Georgia Bio for AbeoMouse™

Posted on January 22nd, 2016

Abeome Corporation announced today it has been named a Georgia Bio Innovation Award Winner.

Abeome Closes $2M Angel Round

Posted on January 5th, 2016

Abeome Corporation announced today the closing of a $2M Angel Round.

Abeome Launches New Website and Brand Refresh

Posted on July 16th, 2015

Abeome announces a new website and brand refresh.

Abeome Receives Grant for AbeoMouse™ Technology

Posted on February 10th, 2014

Abeome Corporation announced today the receipt of an award letter for a Small Business Innovative Research (SBIR) grant in the amount of $217,860 over 10 months.

Abeome Corporation Receives Grant to Study Obesity

Posted on March 15th, 2013

Abeome Corporation announced today the receipt of an award letter for a Small Business Innovative Research (SBIR) grant in the amount of $275,916 over 10 months. The grant, titled “Semi-Targeted Immunotherapeutic Approach for Treatment of Obesity,” is a Phase 1 grant focused on generating a large number of monoclonal antibodies to human preadipocytes, the cells that are the precursors to fat cells.

Abeome Receives Grant for AbeoMouse™ Technology

Posted on March 1st, 2013

Abeome has entered into a non-exclusive agreement with Enzo Life Sciences (NASDAQ: ENZO) to distribute core technology (DiSH™) and related growth media components in the form of kits to Enzo’s worldwide network of life science customers.